Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Europe 9 Top Countries Contributing to Clinical Trials in North America 10 Top Countries Contributing to Clinical Trials in Middle East and Africa 11 Top Countries Contributing to Clinical Trials in Central and South America 12 Clinical Trials by G7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 13 Clinical Trials by Phase in G7 Countries 14 Clinical Trials in G7 Countries by Trial Status 15 Clinical Trials by E7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 16 Clinical Trials by Phase 18 In Progress Trials by Phase 19 Clinical Trials by Trial Status 20 Clinical Trials by End Point Status 21 Subjects Recruited Over a Period of Time 22 Clinical Trials by Sponsor Type 23 Prominent Sponsors 24 Top Companies Participating in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials 25 Prominent Drugs 27 Latest Clinical Trials News on Familial Chylomicronemia (Type I Hyperlipoproteinemia) 28 Jun 27, 2016: Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes 28 Clinical Trial Profile Snapshots 29 Appendix 38 Abbreviations 38 Definitions 38 Research Methodology 39 Secondary Research 39 About GlobalData 40 Contact Us 40 Disclaimer 40 Source 41

List of Tables Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2016* 6 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2016* 10 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 11 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 12 Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 13 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15 Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2016* 18 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 19 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 23 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27 List of Figures Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 11 Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 13 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15 Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 16 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 18 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 19 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 23 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27 GlobalData Methodology 39

Ionis Pharmaceuticals, Inc. Novartis AG Medpace Holdings, Inc. Aegerion Pharmaceuticals, Inc. UniQure N.V. Richmond Pharmacology Limited Kadmon Corporation, LLC ICON Plc Catabasis Pharmaceuticals, Inc.